1
Return

Standard: human breast cancer organoids derived from diverse clinical sample sources

delete2026-06-16
delete0
delete
OA
AI
Z
Zhigang Chen
N
Ningning Xu
M
Ming Chen
J
Jianming Hu
Z
Zhuohang Yu
S
Sangsang Zhu
Y
Yi Zhang
R
Ronghao Zhang
K
Kun Wang
S
Shu Wang
D
Dong Gao
F
Fei Ma
J
Jin Zhang
J
Jiong Wu
B
Binghe Xu
E
Erwei Song
J
Jian Huang *
DOI:10.1186/s13619-026-00291-zdelete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Breast cancer remains a leading cause of cancer-related morbidity and mortality worldwide, driven by therapeutic resistance, recurrence, and metastasis. Patient-derived organoids (PDOs) have emerged as a robust platform that preserves histopathological, genetic, and functional features of parental tumors, enabling translational research and precision oncology. However, the lack of standardized procedures across laboratories limits reproducibility and clinical applicability. Here, we present a consensus-oriented standard for the establishment, characterization, quality control and application of human breast cancer organoids derived from diverse clinical sources, including surgical tissues, biopsies, pleural effusion, ascites, and circulating tumor cells (CTCs). This document defines key terminologies, outlines standardized workflows, and introduces quantitative validation criteria for successful organoid establishment. In addition, it provides structured guidance for advanced models, including immune–tumor, neuro–tumor, and microbiota−tumor organoid systems, with defined functional validation endpoints. Standardized protocols for drug sensitivity testing are also proposed, including seeding density, exposure duration, and response metrics such as IC50 and AUC. Representative validation strategies, including histological, molecular and functional concordance with parental tumors, are incorporated to enhance reproducibility and translational relevance. This standard aims to harmonize methodologies, improve cross−study comparability, and accelerate the clinical implementation of breast cancer organoid-based precision medicine.
Keywords:
Standard
Breast cancer
Organoids
Drug sensitivity
Personalized treatment
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Cell Regeneration cover
Cell Regeneration
IF:
4.7
Papers:
233
Citations:
654

Organization

B
Breast Center
Scholars:
98
Papers: 49
Citations: 572
S
second affiliated hospital
Scholars:
181
Papers: 45
Citations: 0
S
Shanghai Institute of Biochemistry and Cell Biology
Scholars:
102
Papers: 34
Citations: 0
N
national cancer center
Scholars:
1.5K
Papers: 456
Citations: 0
S
shanghai medical college
Scholars:
311
Papers: 98
Citations: 1
T
treatment and research center
Scholars:
2
Papers: 1
Citations: 0
S
Sun Yat-sen Memorial Hospital
Scholars:
657
Papers: 191
Citations: 7.1K
G
Guangdong Provincial People's Hospital
Scholars:
525
Papers: 137
Citations: 7.3K
Cited Papers

Cited Papers

Citing Papers

Citing Papers